Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy - Ravandi, Farhad; Jorgensen, Jeffrey L.; Thomas, Deborah A.; O'Brien, Susan; Garris, Rebecca; Faderl, Stefan; Huang, Xuelin; Wen, Sijin; Burger, Jan A.; Ferrajoli, Alessandra; Kebriaei, Partow; Champlin, Richard E.; et al. (Blood, 2013)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzamides - administration & dosage; Cyclophosphamide - administration & dosage; Cytarabine - administration & dosage; Dasatinib; Dexamethasone - administration & dosage; Doxorubicin - administration & dosage; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl - genetics; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains - genetics; Lymphoid Neoplasia; Male; Methotrexate - administration & dosage; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - mortality; Neoplasm Staging; Neoplasm, Residual - diagnosis; Neoplasm, Residual - genetics; Neoplasm, Residual - mortality; Philadelphia Chromosome; Piperazines - administration & dosage; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality; Prednisone - administration & dosage; Prognosis; Pyrimidines - administration & dosage; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; Survival Rate; Thiazoles - administration & dosage; Vincristine - administration & dosage; Young Adult